Status:
COMPLETED
Phosphorylation of ERK1/2 in Patients With Parkinson's Disease
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Université Victor Segalen Bordeaux 2
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-85 years
Brief Summary
Levodopa-induced dyskinesia severely limits the use of levodopa in Parkinson's disease and constitutes a debilitating complication of dopaminergic treatment in late stage. Among several neurobiologica...
Eligibility Criteria
Inclusion
- Consecutive eligible PD in- and outpatients selected at the university hospital of Bordeaux.
- Non-demented patients (DSM IV) who are able to give their informed consent and who are affiliated to the social security.
- Controls: Subjects without known neurological disorder, non-demented, able to give their informed consent and affiliated to the social security.
Exclusion
- Patients: Atypical or secondary parkinson disease.
- Previous or current cancer or malignant haemopathy.
- Known auto-immune disease.
- Anti-neoplastic or immuno-modulator treatment (particularly corticosteroids). Immuno-deficient subjects.
- Acute viral infection (within 2 weeks after resolving). Statin drug intake. Demented subject (DSMIV).
- Controls: Same criteria as above plus any neurological disease.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01142739
Start Date
June 1 2010
End Date
July 1 2012
Last Update
July 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux Hôpital Haut Lévêque
Pessac, France, 33604